Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 28, 2019; 25(24): 3069-3078
Published online Jun 28, 2019. doi: 10.3748/wjg.v25.i24.3069
Published online Jun 28, 2019. doi: 10.3748/wjg.v25.i24.3069
Table 1 Patient characteristics
Young (≤ 50 yr) | Old (> 50 yr) | P value | |
(n = 45) | (n = 405) | ||
Sex (male) | 39/45 (87%) | 342/405 (84%) | 0.86 |
Ethnicity (white) | 43/44 (98%) | 377/387 (97%) | 0.70 |
BMI, kg/m2 (mean ± SD) | 29.69 ± 6.05 | 28.53 ± 5.72 | 0.09 |
BMI > 30 kg/m2 | 21/44 (48%) | 124/389 (32%) | 0.04 |
Diabetes | 5/45 (11%) | 91/390 (23%) | 0.01 |
Hypertension | 13/45 (29%) | 211/382 (55%) | < 0.001 |
Family history of malignancy | 21/44 (48%) | 234/382 (61%) | 0.08 |
Family history of esophageal adenocarcinoma | 1/44 (2%) | 17/382 (5%) | 0.78 |
GERD symptoms | 24/44 (55%) | 148/386 (38%) | 0.04 |
Smoking | |||
Ever smoking | 25/44 (57%) | 297/393 (76%) | 0.01 |
Current smoking | 4/44 (9%) | 47/392 (11%) | 0.75 |
Pack-years (mean ± SD) | 13.97 ± 15.56 | 23.46 ± 27.21 | 0.02 |
Alcohol | |||
Ever alcohol | 37/45 (82%) | 297/387 (77%) | 0.52 |
Current alcohol | 31/45 (69%) | 241/375 (64%) | 0.54 |
Medication use | |||
Proton pump inhibitors | 38/43 (88%) | 335/374 (90%) | 0.98 |
Low-dose aspirin | 5/45 (11%) | 130/388 (34%) | < 0.01 |
NSAIDs | 4/45 (9%) | 34/384 (9%) | 0.79 |
Statins | 10/45 (22%) | 189/388 (49%) | < 0.001 |
Endoscopy | |||
Prague C, median (IQR), cm | 2 (0-5) | 1 (0-5) | 0.52 |
Prague M, median (IQR), cm | 4 (2-7) | 4 (2-7) | 0.43 |
Hiatus hernia | 35/45 (78%) | 350/405 (86%) | 0.12 |
Table 2 Adenocarcinoma/high-grade dysplasia risk according to multivariate analysis: Young vs old
Adjusted Odds ratio | 95% confidence interval | P value | |
BMI > 30 | 2.06 | 1.07-3.98 | 0.03 |
Ever smoking | 0.39 | 0.20-0.75 | < 0.01 |
Ongoing GERD symptoms | 2.00 | 1.04-3.85 | 0.04 |
Family history of esophageal adenocarcinoma | 0.73 | 0.09-5.85 | 0.77 |
Ethnicity (white) | 0.77 | 0.09-6.42 | 0.81 |
Sex (Male) | 1.44 | 0.56-3.70 | 0.45 |
Table 3 Pathological features of esophageal adenocarcinoma, n (%)
Young (≤ 50 yr) | Old (> 50 yr) | P value | ||
(n = 45) | (n = 405) | |||
Histology | EAC | 31 (69) | 317 (78) | 0.15 |
HGD | 14 (31) | 88 (22) | ||
EAC depth | M1 | 7 (23) | 63 (20) | |
M2 | 8 (26) | 75 (24) | ||
M3 | 8 (26) | 47 (15) | ||
M4 | 4 (13) | 96 (30) | ||
SM | 4 (13) | 36 (11) | 0.41 | |
Differentiation | G1 | 21 (68) | 212 (67) | |
G2 | 6 (19) | 91 (29) | ||
G3 | 4 (13) | 14 (4) | 0.22 | |
Lympho-vascular invasion | 1 (3) | 32 (10) | 0.36 | |
Vertical margin positive rate | 3 (10) | 32 (10) | 0.81 |
Table 4 Clinical outcomes following endoscopic treatment
Young (≤ 50 yr) | Old (> 50 yr) | P value | |
(n = 30) | (n = 257) | ||
Complete eradication of neoplasia | 28/30 (93%) | 220/257 (86%) | 0.38 |
Recurrence of neoplasia | 4/28 (14%) | 40/220 (18%) | 0.81 |
Complete eradication of intestinal metaplasia | 23/30 (77%) | 159/257 (62%) | 0.16 |
Recurrence of intestinal metaplasia | 7/23 (30%) | 41/159 (26%) | 0.83 |
- Citation: Iwaya Y, Shimamura Y, Goda K, Rodríguez de Santiago E, Coneys JG, Mosko JD, Kandel G, Kortan P, May G, Marcon N, Teshima C. Clinical characteristics of young patients with early Barrett’s neoplasia. World J Gastroenterol 2019; 25(24): 3069-3078
- URL: https://www.wjgnet.com/1007-9327/full/v25/i24/3069.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i24.3069